Dermatomyositis is an idiopathic inflammatory myopathy with characteristic
skin manifestations. Although the disorder is rare, with a prevalence of on
e to 10 cases per million in adults and one to 3.2 cases per million in chi
ldren, early recognition and treatment are important ways to decrease the m
orbidity of systemic complications. An association with other connective ti
ssue disorders (overlap syndrome) and malignancy make this diagnosis partic
ularly important to primary care physicians. Patient management includes ca
reful evaluation for underlying malignancy and liberal use of physical ther
apy, antihistamines, sunscreen and oral corticosteroids. Poor prognostic in
dicators include poorly responsive disease, delay in diagnosis and the pres
ence of malignancy. The therapeutic goal is to maintain function and preven
t or minimize sequelae.